SCHEMBL3088056

SCHEMBL3088056

C=CCCC(OS(=O)(=O)O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.39
SRC P12931 1/20 0.35
ALDH1A1 P00352 2/20 0.34
GSR P00390 1/20 0.34
TDP1 Q9NUW8 3/20 0.34
MAPT P10636 2/20 0.33
KMT2A Q03164 3/20 0.33
POLB P06746 2/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
LMNA P02545 3/20 0.32
MAPK1 P28482 1/20 0.32
MMP13 P45452 1/20 0.31
KDM4E B2RXH2 2/20 0.31
NPSR1 Q6W5P4 2/20 0.31
HSD11B1 P28845 1/20 0.31
GMNN O75496 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083588 0.91 TDP1 (0.38) CYP2C19SRCALDH1A1GSRTDP1
SCHEMBL3094432 0.90 TDP1 (0.37) CYP2C19SRCALDH1A1GSRTDP1
SCHEMBL3087780 0.88 TDP1 (0.36) CYP2C19SRCALDH1A1GSRTDP1
SCHEMBL3069638 0.88 TDP1 (0.36) CYP2C19SRCALDH1A1GSRTDP1
SCHEMBL3076090 0.88 TDP1 (0.36) CYP2C19SRCALDH1A1GSRTDP1
SCHEMBL3089633 0.88 TDP1 (0.36) CYP2C19SRCALDH1A1GSRTDP1
SCHEMBL3074653 0.88 TDP1 (0.36) CYP2C19SRCALDH1A1GSRTDP1
SCHEMBL3091268 0.84 CYP2C19 (0.49) CYP2C19SRCALDH1A1GSRTDP1
SCHEMBL10889739 0.78 CYP2C19 (0.39) CYP2C19ALDH1A1GSRMAPTKMT2A
SCHEMBL2991652 0.76 CYP2C19 (0.46) CYP2C19SRCALDH1A1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150132797-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING LIFE TECHNOLOGIES CORP (US) 2015-05-14 US claimed
US-20080038772-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US claimed
US-20080038773-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US claimed
US-20150132797-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING LIFE TECHNOLOGIES CORP (US) 2015-05-14 US disclosed
US-20100172861-A1 Anionic Polymers as Toxin Binders and Antibacterial Agents GENZYME CORPORATION (US) 2010-07-08 US disclosed
US-7678369-B2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2010-03-16 US disclosed
US-20080038772-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US disclosed
US-20080038773-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US disclosed
EP-1189622-B1 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS GENZYME CORP (US) 2007-07-25 EP disclosed
EP-1800687-A2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2007-06-27 EP disclosed
EP-1800686-A2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2007-06-27 EP disclosed
US-20060029568-A1 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents GENZYME CORPORATION (US) 2006-02-09 US disclosed
US-6890523-B2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2005-05-10 US disclosed
US-20030138397-A1 Anionic polymers as toxin binders and antibacterial agents GELTEX PHARMACEUTICALS, INC. 2003-07-24 US disclosed
US-6517827-B1 Polystyrene sulfonate polymer; Clostridium difficile GELTEX PHARMACEUTICALS, INC. 2003-02-11 US disclosed
US-6517826-B1 Polystyrene sulfonate polymer; Clostridium difficile GELTEX PHARMACEUTICALS, INC. 2003-02-11 US disclosed
EP-1189622-A2 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS Geltex Pharmaceuticals, Inc. (US) 2002-03-27 EP disclosed
US-6290946-B1 ADMINISTERING TO THE ANIMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A POLYMER HAVING A PLURALITY OF PENDANT ACID FUNCTIONAL GROUPS WHICH ARE DIRECTLY ATTACHED TO THE POLYMER BACKBONE OR ATTACHED TO THE POLYMER BACKBONE BY A SPACER GROUP. GELTEX PHARMACEUTICALS, INC. 2001-09-18 US disclosed
WO-2000069428-A2 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS GELTEX PHARMACEUTICALS, INC. (US) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100172861-A1 Anionic Polymers as Toxin Binders and Antibacterial Agents MSN, ANTXR2, PNKP CYP2C19 4744/4885SRC 3822/4885ALDH1A1 4470/4885
US-20060029568-A1 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents DDOST, DNPEP, IDUA CYP2C19 4413/4885SRC 3302/4885ALDH1A1 1727/4885
US-20030138397-A1 Anionic polymers as toxin binders and antibacterial agents MSN, ANTXR2, PNKP CYP2C19 4744/4885SRC 3822/4885ALDH1A1 4470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.